Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer pulls all lots of sickle cell disease drug
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Pfizer pulls all lots of sickle cell disease drug from market
Pfizer has announced the withdrawal of all lots of Oxbryta, its drug for sickle cell disease, amid concerns about increased complications and fatal events. The decision, effective immediately in all approved markets,
Deaths lead Pfizer to pull sickle cell drug at center of $5 billion Bay Area buyout
Pfizer had big hopes for a sickle-cell disease drug, as did those suffering from the disease. Things didn't turn out as planned.
2d
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...
2d
Updated Pfizer-BioNTech’s COVID-19 vaccine approved by Health Canada
Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...
8d
on MSN
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
3d
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...
7d
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
EuropaWire
6d
Pfizer and BioNTech’s Omicron KP.2-Adapted COVID-19 Vaccine Receives Positive EU Opinion, Awaiting Approval
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
3d
Health Canada approves Pfizer-BioNTech's updated COVID-19 vaccine
BioNTech's updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.
Business Insider
1d
Pfizer’s Hold Rating: Evaluating the Impact of Oxbryta Withdrawal and Pipeline Uncertainties
While
Pfizer
is developing a next-generation version of Oxbryta ... Flynn covers the Healthcare sector, focusing on stocks such as
BioNTech
SE, Eli Lilly & Co, and Regeneron. In another report ...
2d
Fall 2024 COVID-19 guide: The status of COVID in Canada, available vaccines — and strains expected to dominate winter
Currently, the KP.3 and KP.3.1.1 FLiRT variants, derivatives of KP.1 and KP.2, are the most prevalent in Canada and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
COVID-19
Comirnaty
North Korea
Novavax
Health Canada
Feedback